Literature DB >> 26973346

Clinical characteristics and outcomes of dialysis patients with atrial fibrillation: the Fushimi AF Registry.

Yugo Yamashita1, Daisuke Takagi2, Yasuhiro Hamatani3, Moritake Iguchi2, Nobutoyo Masunaga2, Masahiro Esato4, Yeong-Hwa Chun4, Hitoshi Itoh5, Masato Nishimura6, Hiromichi Wada7, Koji Hasegawa7, Hisashi Ogawa2, Mitsuru Abe2, Masaharu Akao8.   

Abstract

Atrial fibrillation (AF) is common in dialysis patients. However, clinical characteristics and outcomes of dialysis patients with AF are poorly understood. The Fushimi AF Registry is a community-based prospective survey of AF patients in Japan. Follow-up data were available for 3713 patients with a median follow-up of 2.8 years. We compared clinical characteristics and outcomes between the dialysis group (n = 92; 2.5 %) and others. The dialysis group had more various co-morbidities, with a mean CHADS2 score of 2.5, and the rate of warfarin prescription was 38 %. The annual incidence rates of stroke or systemic embolism (SE), major bleeding, and all-cause death in the dialysis group were 4.0, 5.1, and 20.9 per 100 person-years, respectively. There was no significant difference in the incidence rate of stroke/SE between the dialysis group and the non-dialysis group [hazard ratio (HR) 1.74 (95 % confidence interval (CI) 0.74-3.42)]. The incidence rates of major bleeding, all-cause death, and the composite of stroke/SE and all-cause death in the dialysis group were higher than those in the non-dialysis group [major bleeding: HR 3.09 (95 % CI 1.46-5.72), all-cause death: HR 3.51 (95 % CI 2.48-4.81), the composite of stroke/SE and all-cause death: HR 2.99 (95 % CI 2.15-4.05)]. Among dialysis patients, warfarin did not affect major clinical events including stroke/SE, bleeding or all-cause death. Among AF patients, those receiving dialysis showed higher incidence of major bleeding and all-cause death compared with non-dialysis patients, but the risk of stroke/SE was not particularly high. CLINICAL TRIAL REGISTRATION: URL: http://www.umin.ac.jp/ctr/index.htm .

Entities:  

Keywords:  Atrial fibrillation; Bleeding; Dialysis; Oral anticoagulant; Stroke

Mesh:

Substances:

Year:  2016        PMID: 26973346     DOI: 10.1007/s00380-016-0818-x

Source DB:  PubMed          Journal:  Heart Vessels        ISSN: 0910-8327            Impact factor:   2.037


  39 in total

1.  Anticoagulant and antiplatelet usage associates with mortality among hemodialysis patients.

Authors:  Kevin E Chan; J Michael Lazarus; Ravi Thadhani; Raymond M Hakim
Journal:  J Am Soc Nephrol       Date:  2009-03-18       Impact factor: 10.121

2.  Warfarin use and the risk for stroke and bleeding in patients with atrial fibrillation undergoing dialysis.

Authors:  Mitesh Shah; Meytal Avgil Tsadok; Cynthia A Jackevicius; Vidal Essebag; Mark J Eisenberg; Elham Rahme; Karin H Humphries; Jack V Tu; Hassan Behlouli; Helen Guo; Louise Pilote
Journal:  Circulation       Date:  2014-01-22       Impact factor: 29.690

3.  2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation--developed with the special contribution of the European Heart Rhythm Association.

Authors:  A John Camm; Gregory Y H Lip; Raffaele De Caterina; Irene Savelieva; Dan Atar; Stefan H Hohnloser; Gerhard Hindricks; Paulus Kirchhof
Journal:  Europace       Date:  2012-08-24       Impact factor: 5.214

Review 4.  Warfarin use and the risks of stroke and bleeding in hemodialysis patients with atrial fibrillation: A systematic review and a meta-analysis.

Authors:  Jingzhen Li; Lijuan Wang; Jinzhu Hu; Gaosi Xu
Journal:  Nutr Metab Cardiovasc Dis       Date:  2015-04-01       Impact factor: 4.222

5.  Risk factors for incident stroke among patients with end-stage renal disease.

Authors:  Stephen L Seliger; Daniel L Gillen; David Tirschwell; Haimanot Wasse; Bryan R Kestenbaum; Catherine O Stehman-Breen
Journal:  J Am Soc Nephrol       Date:  2003-10       Impact factor: 10.121

6.  Comparison of prognostic value of atrial fibrillation versus sinus rhythm in patients on long-term hemodialysis.

Authors:  Eduardo Vázquez; Carmen Sánchez-Perales; Cristóbal Lozano; Ma José García-Cortés; Francisco Borrego; Manuel Guzmán; Pilar Pérez; Carlos Pagola; Ma José Borrego; Vicente Pérez
Journal:  Am J Cardiol       Date:  2003-10-01       Impact factor: 2.778

7.  Atrial fibrillation and morbidity and mortality in a cohort of long-term hemodialysis patients.

Authors:  Simonetta Genovesi; Antonio Vincenti; Emanuela Rossi; Daniela Pogliani; Irene Acquistapace; Andrea Stella; Maria Grazia Valsecchi
Journal:  Am J Kidney Dis       Date:  2008-02       Impact factor: 8.860

8.  Current status of clinical background of patients with atrial fibrillation in a community-based survey: the Fushimi AF Registry.

Authors:  Masaharu Akao; Yeong-Hwa Chun; Hiromichi Wada; Masahiro Esato; Tetsuo Hashimoto; Mitsuru Abe; Koji Hasegawa; Hikari Tsuji; Keizo Furuke
Journal:  J Cardiol       Date:  2013-02-08       Impact factor: 3.159

9.  Warfarin use and incidence of stroke in Japanese hemodialysis patients with atrial fibrillation.

Authors:  Kenji Yodogawa; Akiko Mii; Megumi Fukui; Yu-Ki Iwasaki; Meiso Hayashi; Tomohiro Kaneko; Yasushi Miyauchi; Shuichi Tsuruoka; Wataru Shimizu
Journal:  Heart Vessels       Date:  2015-12-08       Impact factor: 2.037

10.  Should patients with advanced chronic kidney disease and atrial fibrillation receive chronic anticoagulation?

Authors:  Catherine M Clase; Rachel M Holden; Manish M Sood; Claudio Rigatto; Louise M Moist; Benjamin K A Thomson; Johannes F E Mann; Deborah L Zimmerman
Journal:  Nephrol Dial Transplant       Date:  2012-10       Impact factor: 5.992

View more
  7 in total

1.  Predictors of thrombus formation after percutaneous left atrial appendage closure using the WATCHMAN device.

Authors:  Hidehiro Kaneko; Michael Neuss; Jens Weissenborn; Christian Butter
Journal:  Heart Vessels       Date:  2017-05-05       Impact factor: 2.037

Review 2.  Atrial fibrillation in dialysis patients: is there a place for non-vitamin K antagonist oral anticoagulants?

Authors:  Elzbieta Mlodawska; Paulina Lopatowska; Jolanta Malyszko; Maciej Banach; Bożena Sobkowicz; Adrian Covic; Anna Tomaszuk-Kazberuk
Journal:  Int Urol Nephrol       Date:  2018-05-21       Impact factor: 2.370

3.  Characterization of baseline clinical factors associated with incident worsening kidney function in patients with non-valvular atrial fibrillation: the Hokuriku-Plus AF Registry.

Authors:  Kenshi Hayashi; Yoshihiro Tanaka; Toyonobu Tsuda; Akihiro Nomura; Noboru Fujino; Hiroshi Furusho; Norihiko Sakai; Yasunori Iwata; Soichiro Usui; Kenji Sakata; Takeshi Kato; Hayato Tada; Takashi Kusayama; Keisuke Usuda; Masa-Aki Kawashiri; Rod S Passman; Takashi Wada; Masakazu Yamagishi; Masayuki Takamura
Journal:  Heart Vessels       Date:  2022-10-17       Impact factor: 1.814

Review 4.  Atrial fibrillation and chronic kidney disease: A review of options for therapeutic anticoagulation to reduce thromboembolism risk.

Authors:  Harpreet S Bhatia; Jonathan C Hsu; Robert J Kim
Journal:  Clin Cardiol       Date:  2018-10-25       Impact factor: 2.882

5.  The influence of atrial fibrillation on the mortality of incident ESRD patients undergoing maintenance hemodialysis.

Authors:  Hui-Ling Hsieh; Shih-Chang Hsu; Ho-Shun Cheng; Chun-You Chen; Wen-Cheng Huang; Yuh-Mou Sue; Feng-Yen Lin; Chun-Ming Shih; Jaw-Wen Chen; Shing-Jong Lin; Po-Hsun Huang; Chung-Te Liu
Journal:  PLoS One       Date:  2020-01-30       Impact factor: 3.240

6.  Estrogen and estrogen receptors in kidney diseases.

Authors:  Hao-Yang Ma; Shuang Chen; Yang Du
Journal:  Ren Fail       Date:  2021-01-01       Impact factor: 2.606

7.  Warfarin and the Risk of Death, Stroke, and Major Bleeding in Patients With Atrial Fibrillation Receiving Hemodialysis: A Systematic Review and Meta-Analysis.

Authors:  Hong Lei; Li-Ting Yu; Wei-Ning Wang; Shun-Guo Zhang
Journal:  Front Pharmacol       Date:  2018-11-06       Impact factor: 5.810

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.